natgillin/translations-raw huggingface dataset:
A sustained release pharmaceutical dosage form comprising 40 mg of oxycodone or a pharmaceutically acceptable salt thereof and 20 mg of naloxone or a pharmaceutically acceptable salt thereof with oxycodone or a pharmaceutically acceptable salt thereof and naloxone or a pharmaceutically acceptable salt thereof being present in a ratio of 2:1 by weight for use in the treatment of moderate to severe pain and opioid bowel dysfunction syndromes occurring during pain therapy, wherein said opioid bowel dysfunction syndrome is constipation, and adverse events, wherein said adverse events are elicited naloxone typical adverse events selected from the group consisting of abdominal pain, cramping and diarrhea. 
PATENTNI ZAHTJEVI Farmaceutski oblik doziranja s produljenim oslobađanjem koji sadrži 40 mg oksikodona ili njegove farmaceutski prihvatljive soli i 20 mg naloksona ili njegove farmaceutski prihvatljive soli, gdje su oksikodon ili njegova farmaceutski prihvatljiva sol i nalokson ili njegova farmaceutski prihvatljiva sol prisutni u težinskom omjeru od 2:1, za upotrebu u liječenju umjerene do jake boli i opioidom izazvanih sindroma crijevne disfunkcije koji se javljaju tijekom terapije protiv bolova, gdje je navedeni opioidom izazvani sindrom crijevne disfunkcije zatvor, i neželjenih efekata, gdje su navedeni neželjeni efekti tipični naloksonom izazvani neželjeni efekti odabrani iz skupine koja se sastoji od bolova u trbuhu, grčeva i dijareje.
(b3) an antigen-binding site comprising an H chain variable region amino acid sequence of SEQ ID NO: 48 (H chain variable region of J268); 
(b3) mjesto vezanja antigena koje obuhvaća aminokiselinsku sekvencu varijabilnog područja H-lanca od SEQ ID NO: 48 (varijabilno područje H-lanca od J268);
A vaporizer 45, a gas-liquid separator 46, and a heater 47 are installed in the sub LNG supply line L24 so as to adjust the methane number and temperature of LNG supplied as fuel to the value required in the DF engine. 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 3, naznačen time što pomoćna linija za slanje LNG (1.24) sadrži separator plina od tekućine (46), podešen za razdvajanje teške ugljikovodične komponente od LNG, kako bi se podesilo metanski broj goriva do vrijednosti potrebne za pomoćni motor.
The apparatus of claim 1, wherein the transponders signal the computer (82) or the PLC to signal the radio receiver. The apparatus of claim 1, wherein the radio receiver further comprises an antenna. 
Uređaj prema zahtjevu 1, naznačen time da transponderi (80) signaliziraju računalu (82) da signalizira radio prijemniku (502) i/ili da aktivira alarm (86).
The shotgun of claim 38 wherein the fastening mechanism pivots outward from the forearm to move from the first position to the second position. 
Puška sukladno Zahtjevu 5, naznačena time što mehanizam za pričvršćivanje zakreće prema van u odnosu na rukohvat kako bi se pomaknuo u prvi i drugi položaj.
It is further disclosed that the ratio by weight of the ligno-cellulosic biomass present in the extraction vessel to the extraction liquid in the extraction vessel may be less than a value selected from the group consisting of 1:1000, 1:800, 1:600, 1:400, 1:200, 1:100, 1:70, 1:50, 1:30, 1:20, and 1:10. 
Proces iz bilo kojeg od patentnih zahtjeva 1 do 11, gdje je odnos po masi ligno-celulozne biomase prisutne u ekstrakcijskoj posudi prema ekstrakcijskoj tekućim u ekstrakcijskoj posudi manji od vrijednosti odabrane iz grupe koja se sastoji od 1:1000, 1:800, 1:600, 1:400, 1:200, 1:100, 1: 70, 1:50, 1:30, 1:20, 1 1:10.
The radio communication method according to claim 7, wherein, the first accumulation value is updated with the TPC command received from two or more nodes in one cell. 
Radio komunikacijski terminalni uređaj sukladno zahtjevu 2, naznačen time da je: prva akumulacijska vrijednost, prije nego što se podvrgne navedenom ažuriranju s naredbom TPC, postavljena na nulu nakon navedenog iniciranja.
The compound of claim 8, wherein R1′ is a benzyl group. A herbicidal composition comprising a compound of claim 1 and an agriculturally acceptable adjuvant or carrier. 
Herbicidni pripravak, naznačen time što sadrži spoj u skladu s bilo kojim od patentnih zahtjeva 1-4, kao i poljoprivredno prihvatljiv adjuvans ili nosač.
Preparation of tetra-omeprazole titanium salt. 
Dobivanje tetra-omeprazol titan soli
It may further be evidenced by reduced requirement for other, symptomatic therapy, i.e., therapy for or intended to restrict or abort symptomatic attack when it occurs, e.g., anti-inflammatory (e.g., corticosteroid) or bronchodilatory. 
Može se, nadalje, vidjeti smanjena potreba za drugom, simptomatičnom terapijom, tj. terapijom za ili predviđenom za ograničenje ili uklanjanje simptomatičnog napada kad se on pojavi, npr. anti-upalnih (npr. kortikosteroida) ili bronhodilatora.
Y represents a carbonyl group or a methylene group optionally substituted by a hydroxyl group; and/or p represents 2 and q represents 0; and more particularly wherein R1, R2, R3, X, Y, p, q, m, o and n are as defined hereinabove. 
Y predstavlja karbonilnu skupinu ili metilensku skupinu, izborno supstituiranu s hidroksilnom skupinom; i/ili p znači 2, a q znači 0; specifičnije gdje R1, R2, R3, X, Y, p, q, m, oin su definirani kao gore.
is C(4-6)cycloalkyl, isopropyl, C(CH3)2OCH3, OCH(CH3)2, difluoropiperidinyl, fluoropiperidinyl, fluorophenyl, or NA1A2, wherein said C(4-6)cycloalkyl is optionally substituted with OCH3, two fluoro groups or two methyl groups; and wherein A1 and A2 are taken together with their attached nitrogen to form a pyrrolidinyl ring, wherein said pyrrolidinyl ring is optionally substituted with CH3, CH2F, and up to three additional substituents selected from the group consisting of CH3, and F; 
R* je Ca-grcikloalkil, izopropil, C(CH3)yOCH:3, OCH(CH3), difluoropiperidinil, fluoropiperidinil, fluorofenil, ili NA 'A', pri čemu je navedeni Ca.gycikloalkil proizvoljno supstituiran s OCH>, dvije fluoro skupine ili dvije metil skupine; i pri čemu A'i A? su uzeti zajedno s dušikovim atomom za koji su vezani da tvore pirolidinil, pri čemu je navedeni prsten pirolidinil proizvoljno supstituiran s CH3, CHDF, 1 do tri dodatna supstituenta odabrana između skupina koje čine CH;, i F;
The composition of claim 8 or claim 9, wherein in the dihydroazole compound of formula (I): is CH2; 
Veterinarski ili agrikulturni sastav prema zahtjevu 8 ili zahtjevu 9, naznačen time, da u spoju dihidroazola formule (I):
a V domain of an anti-CD3 antibody comprising a VL domain comprising SEQ ID NO: 10 and/or a VH domain comprising SEQ ID NO: 9; and 
V domena protutijela protiv CD3, koja sadrži VL domenu koja sadrži SEQ ID NO: 10 i/ili VH domenu koja sadrži SEQ ID NO: 9; i
wherein R1 is difluoromethyl or trifluoromethyl and X is chloro, fluoro or bromo; and (B) at least one compound selected from compounds known for their fungicidal activity; and a method of controlling diseases on useful plants, especially rust diseases on soybean plants. 
Pripravak koja je pogodan za kontrolu bolesti koje uzrokuju fitopatogeni, naznačen time što sadrži (A) spoj formule (I) pri čemu je R1 difluorometil ili trifluorometil i X je kloro, fluoro ili bromo; te (B) spoj ciprodinil.
Frequently, more often during the first steps of the processing, the lower concentrated polyunsaturated substances are partially concentrated f.i. 
Često, još češće tijekom prvih koraka procesuiranja, niže koncentrirane polinezasićene tvari se djelomično koncentriraju npr.
After THF was removed, the residue was taken up in ethyl acetate, washed with 1 N HCl, H2O, and brine, then was dried over Na2SO4, and concentrated. 
Nakon uklanjanja THF-a ostatak se preuzme u etil-acetat, ispere s 1 N HCI, H,0, te slanom vodom, zatim osuši preko Na2504, te koncentrira.
The process of any one of claims 1 to 3, wherein said alcohol is selected from the group consisting of methanol, ethanol, propanol, isopropanol, butanol, sec-butanol, t-butanol, pentanol, and octanol, and mixtures of 2 or more thereof. 
Postupak u skladu s patentnim zahtjevom 14, naznačen time što navedeni alkohol se bira iz skupine koju čine metanol, etanol, propanol, izopropanol, butanol, sec-butanol, t-butanol, pentanol, oktanol, te smjese 2 ili više njih.
Embodiment 11. Process according to Embodiment 10 characterized in that the shell and tube type heat exchanger is of the U-tube type. 
Postupak sukladno zahtjevu 8 naznačen time što je izmenjivač topline tipa sa cjevnim omotačem 1 cijevima u obliku slova U.
an annular shoulder (8) defined on the inner face of said first side wall (3) and on which the peripheral edge of said lid (5) is fixed; characterised in that it further comprises: 
- prstenastog naslona (8) postavljenog na unutarnjoj površini navedene prve bočne stijenke (3) i na koju je pričvršćen periferni rub navedenog poklopca (5); naznačena time, da nadalje obuhvaća:
The device according to claim 2, wherein at least one of the first and second engaging members is adapted to at least in part be invaginated by the stomach wall by stomach-to-stomach sutures or staplers holding the engaging member in place. 
Uređaj u skladu s patentnim zahtjevom 2, naznačen time što je najmanje jedan od prvog 1 drugog međudjelujućeg elementa prilagođen da bude u najmanju ruku djelomično invaginiran stijenkom želuca međuželučanim kirurškim šavovima ili kopčama koji drže međudjelujući element na mjestu.
5'- adding the neutralizing agent until achieving the suitable pH for polymer gelling. 
' dodavanja sredstva za neutraliziranje dok se ne postigne pH između 4 i 5, pogodan za želiranje polimera i primjena u vaginu.
A method according to any preceding claim, further comprising a step of separating impurities from the slurry before or after the heating step. 
Postupak u skladu s bilo kojim prethodnim patentnim zahtjevom, naznačen time što dodatno obuhvaća korak izdvajanja nečistoća iz mulja prije 1li nakon koraka grijanja.
Another object of the present invention is to provide a shoe with breathable and waterproof sole and upper that can be manufactured by resorting to the direct injection of polymeric material. 
Drugi je cilj predmetnog izuma omogućiti cipelu s prozračnim i vodootpornim potplatom i gornjištem koja se može proizvesti izravnim injektiranjem polimernog materijala.
Because the C-9 hydroxyl is very susceptible to oxidation, it is preferred that there are no oxidizing reagents present in the reaction to add the methylthiomethyl ether to the modified taxane. 
Budući da je C-9 hidroksil vrlo podložan oksidaciji, poželjno je da ovdje nema prisutnih oksidirajućih reagensa u reakciji kojom se dodaje metiltiometil eter modificiranom taksanu.
a core having a substantially inflexible outer surface, and at least one tool being attached to the surface of the core, wherein flexible force absorbing means is provided in at least a part of the tool plan and/or the reaction plan, so as to locally absorbing the forces applied by the planes. 
- jezgrom koja ima vanjsku površinu koja uglavnom nije fleksibilna, i - najmanje jednim alatom koji je pričvršćen na površinu jezgre, pri čemu je predviđeno fleksibilno sredstvo za apsorbiranje sile u najmanje jednom dijelu ploče za alat i/ili reakcijske ploče, tako da se lokalno apsorbiranje sila primjenjuje pomoću ploča.
or a pharmaceutically acceptable salt thereof, and a compound of formula (I-R): 
ZI" ili njegove farmaceutski prihvatljive soli, i spoja formule (I-R):
The vector of claim 4, wherein the pathogen specific antigen is derived from human immunodeficiency virus, simian immunodeficiency virus, herpes simplex virus type 1(HSV1), herpes simplex virus type 2 (HSV2), hepatitis B virus, human papillomavirus, or Mycobacterium tuberculosis. 
Vektor prema patentnom zahtjevu 4, naznačen time, da je patološki specifičan antigen izveden iz virusa humane imunodeficijencije, simian virusa imunodeficijencije ili Mycobacterium tuberculosis.
The use of a lipochitooligosaccharide of formula (I) as defined in claim 1 or claim 2 to stimulate the root system development of a plant. 
Uporaba smjese lipokitooligosaharida iz bilo kojeg od patentnih zahtjeva 1 do 2 zbog stimulacije razvoja sustava korijena biljke.
The gear pump 8a is conventional, for example of the type for pumping molten thermoplastic material and delivering a head of at least 400 bar, coupled to a drive unit 11a by a cardan shaft 10a and supported by a suitable support 12a. 
Zupčana pumpa 8a je konvencionalna, na primjer, takve vrste da se pomoću nje pumpa termoplastični materijal 1 isporučuje vršno barem 400 bara, i povezana je na pogonsku jedinicu 11a preko kardanske osovine 10a 1 postavljena je na prikladni nosač 12a.
The tetrabenazine used as the starting material for the reduction to give the dihydrotetrabenazine can be obtained commercially or can be synthesised by the method described in US 2,830,993 (Hoffmarin-La Roche). 
Tetrabenazin koji se koristi kao polazni materijal za redukciju da bi se dobio dihidrotetrabenazin, se može nabaviti komercijalno ili se može sintetizirati postupkom opisanim u US 2,830,993 (Hoffmann-La Roche).
the separated zofenopril calcium is dried under reduced pressure at a temperature of up to 85°C. 
(xi) razdvojeni zofenopril kalcij je osušen pod sniženim tlakom na temperaturi do 85%C.
a compound selected from the group consisting of sulfonamides, including their respective isomers a s well as their respective environmentally compatible salts or esters or amides or other derivatives; 
Sinergistička herbicidna smjesa koja sadrži imazamoks, njegove odgovarajuće izomere, kao i njegove odgovarajuće soli, estere, amide ili druge derivate kompatibilne sa životnom sredinom;
The process of claim 35 wherein the protic or aprotic solvent is selected from the group consisting of THF, DMF, DMA, and ethanol, or a mixture thereof. 
36. Postupak prema zahtjevu 35, gdje je protonsko ili aprotonsko otapalo izabrano iz grupe koja se sastoji od THF, 30
The scope of the present disclosure is rather to be determined by the scope of the claims as issued and equivalents thereto. A method of enhancing muscle regeneration or repair in a subject comprising systemically administering a therapeutically effective amount of laminin-1 to the subject in need thereof. 
Neka terapeutski djelotvorna količina laminina-1 za pospješivanje regeneracije mišića ili zacjeljivanja kod neke osobe, ili za sprječavanje ili smanjenje oštećenja mišića neke osobe, naznačena time da se laminin-1 daje sistemski i da se ta regeneracija mišića provodi nakon oštećenja, ozljede ili bolesti.
The adhesive layer preferably includes using any adhesive known in the art that is pharmaceutically compatible with the dosage form and preferably hypoallergenic, such as polyacrylic adhesive polymers, acrylate copolymers (e.g. polyacrylate) and polyisobutylene adhesive polymers. 
Preferira se da se za ljepljivi sloj koristi bilo koje sredstvo za lijepljenje poznato u struci koje je farmaceutski kompatibilno s dozom, a preferira se da je hipoalergensko, kao što su poliakrilni ljepljivi polimeri, akrilat kopolimeri (npr., poliakrilat) te poliizobutilen ljepljivi polimeri.
In table 12 it is shown how the compound (12) reduces both the area of the atherosclerotic lesions and the area covered with macrophages. 
U tablici 12 se vidi kako spoj (12) smanjuje oboje, površinu ateroskleroznih lezija i površinu pokrivenu s makrofagima.
A purified anti-Factor XI (FXI) antibody or biologically active fragment thereof which specifically binds human FXI described in SEQ ID NO: 1, wherein said antibody or biologically active fragment thereof comprises six complementarity-determining region (CDR) regions, wherein said CDR regions have the amino acid sequences set forth in SEQ ID NO's: 10, 11, 12, 13, 14 and 15. 
Izolirano monoklonsko protutijelo ili njegov fragment koji veže antigen, naznačeno time, da se specifično veže na ljudski faktor koagulacije XI (FXI) opisan u SEQ ID NO: 1, pri čemu protutijelo ili fragment inhibira trombozu bez nanošenja štete sustavu hemostaze, te time da navedeno protutijelo:
the coding unit determiner (120) generates the information about a size of a transformation unit of the coding unit of the coded depth, wherein at least one transformation unit are obtained, according to the size of a transformation unit, by dividing a height and a width of the coding unit of the current depth or to be a data unit of the same size as the coding unit of the current depth and transformation is performed on the coding unit of the current depth based on the at least one transformation unit. 
HR P20182053 T1 određivač jedinice za kodiranje (120) generira informaciju o veličini jedinice za transformaciju od jedinice kodiranja dubine kodiranja, pri čemu se dobiva barem jedna jedinica za transformaciju, prema veličini transformacijske jedinice, dijeljenjem visine i širine jedinice kodiranja trenutne dubine ili da podatkovna jedinica bude iste veličine kao jedinica kodiranja trenutne dubine 1 transformacija se izvršava na jedinici kodiranja trenutne dubine temeljeno na barem jednoj transformacijskoj jedinici.
Ar is phenyl; and Q is optionally substituted aryl or heteroaryl. 
Arje fenil; 1 Q je po izboru supstituirani aril ili heteroaril.
The antibody molecule composition according to at least one of the claims 19 to 31, 34 and 35, wherein the antibody is an antibody against HER2, or against epidermal growth factor receptor (EGFR). 
Pripravak s molekulom protutijela u skladu s najmanje jednim od patentnih zahtjeva 19 do 31, 34 1 35, naznačen time što je protutijelo protutijelo protiv HER2, ili protutijelo protiv receptora čimbenika rasta epiderme (EGFR).
The composition of claim 1, wherein the 4-1BB costimulatory signaling region is encoded by a nucleic acid sequence comprising SEQ ID NO: 17. 
(iv) signalno područje 4-IBB je kodirano sekvencom SEQ ID NO: 17 i signalno područje CD3 zeta je kodirano sekvencom SEQ ID NO:18;
Such conditions include, but are not limited to, inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, viral disease, fibrotic disease and neurodegenerative diseases. 
Upotreba u skladu s patentnim zahtjevom 9, naznačena time što je navedeno stanje posredovano kinazama upalna bolest, autoimuna bolest, destruktivni poremećaj kostiju, proliferativni poremećaj, zarazna bolest, virusna bolest, ili neurodegenerativna bolest.
Use of an acceleration sensor for determining a displacement of an anchor (1) by integrating, preferably numerically, measured acceleration values twice over time; preferably in a method according to one of claims 1 through 6. 
13. Upotreba senzora ubrzanja za određivanje pomaka sidra (1) integrirajući, po mogućnosti numerički, izmjerene vrijednosti ubrzanja tijekom vremena; u postupku prema jednom od patentnih zahtjeva od I do 6.
The process according to claim 11, wherein the saturated aliphatic monocarboxylic acid is formic acid, acetic acid or trifluoroacetic acid. 
Postupak prema patentnom zahtjevu 2, naznačen time što zasićena alifatska kiselina je mravlja, octena ili trifluoroctena kiselina.
The solid dosage form of claim 1, wherein said particles (A) constitute a solid dispersion of amorphous bardoxolone methyl in a glassy matrix. 
Čvrsti oblik doziranja u skladu s patentnim zahtjevom 1, naznačen time što navedene čestice (A) su čvrsta disperzija amorfnog bardoksolon metila u staklastom matriksu.
Top coat: Aqualux™ from Teknos A/S Denmark, a water based UV-curable PU-acrylate dispersion with a dry content of approx. 40%. 
2) Gornji sloj; AqualuxTM tvrtke Teknos A/S Danska, UV zračenjem učvršćena PU-akrilna disperzija na vodenoj osnovi s udjelom suhe tvari od otprilike 40 %.
The method for preparing a pharmaceutical composition according to claim 3 or 5, wherein the organic solvent is ethanol or acetone, preferably ethanol. 
Postupak dobivanja farmaceutskog pripravka sukladno patentnom zahtjevu 1 ili 4, pri čemu je organsko otapalo etanol ili aceton, poželjno etanol.
Netupitant for use according to claims 1-8, comprising treating nausea and vomiting in response to highly emetogenic chemotherapy during the acute phase, or in response to highly emetogenic chemotherapy during the delayed phase. 
Netupitant za uporabu u skladu s patentnim zahtjevima 1-7, obuhvaća liječenje mučnine i povraćanja kao odgovora na vrlo emetogenu kemoterapiju za vrijeme akutne faze, ili kao odgovor na vrlo emetogenu kemoterapiju tijekom odgođene faze.
12 of the crucible of FIG. 
Datum objave europskog patenta:
System according to claim 2, wherein the baseplate (3) is a PVC plate and its thickness is between 0.20 mm and 0.80 mm. 
Sustav prema zahtjevu 2, naznačen time da je osnovna ploča (3) je PVC ploča 1 njezina debljina je između 0,20 mm i 0,80 mm.
This contact may be enhanced by pressing first member 17 and second member 18 together, see Figures 6 and 7, as discussed above. 
HR P20080434 T3 mogu biti izvedene točke spajanja ili područja spajanja pritiskanjem zajedno prvog elementa 17 i drugog elementa 18, vidi slike 6 i 7.
Use according to claim 20, in which said autoimmune disease is selected from the group consisting of systemic lupus crythematosus (SLE), multiple sclerosis (MS), arthritis, diabetes, thyroiditis, haemolytic anaemia, atrophic orchitis, Goodpasture's disease, autoimmune retinopathy, autoimmune thrombocytopenia, myasthenia gravis, primary biliary cirrhosis, aggressive chronic hepatitis, ulcerative colitis, dermatitis, chronic glomerulonephritis, Sjögren's syndrome, Reiter's syndrome, myositis, systemic sclerosis and polyarthritis. 
Primjena prema zahtjevu 20, kod koje je autoimuna bolest izabrana iz grupe koja se sastoji od sistemskog lupus eritematosusa (SLE), multiple skleroze (MS), artritisa, dijabetesa, tiroiditisa, hemolitičke anemije, atrofičnog orhitisa, Goodpasturovc bolcsti, autoimune retinopatije, autoimune trombocitopenije, mijastenije gravis, primarne bilijarne ciroze, agresivnog kroničnog hepatitisa, ulcerativnog kolitisa, dermatitisa, kroničnog glomerulonefritisa, Sjogrenovog sindroma, Reiterovog sindroma, miozitisa, sistemske skleroze i poliartritisa.
The method of claim 2, wherein the aminooxy compound is chosen from compounds of Formula III: wherein Y is the second reactive group, n is chosen from integers ranging from 1 to 10, and P is chosen from amino protecting groups. 
UNS H Formula lil pri čemu Y je druga reaktivna skupina, n je odabran od cijelih brojeva u rasponu od 1 do 10, i P je odabran od amino zaštitnih skupina.
The pyridone derivative, or a salt thereof, according to any of claims 1 to 4, wherein R3 in the formula (I) represents a hydrogen atom, a fluorine atom, or a methyl group. 
Derivat piridona ili njegova sol prema patentnim zahtjevima 1 do 4, naznačen time da je R3 u formuli (I) atom vodika, atom fluora ili metil grupa.
The animals did not recover. 
Životinje se nisu oporavile.
The compound according to claim 48 or a pharmacologically acceptable salt thereof, wherein A is a cyclohexyl group substituted by a methyl group or an ethyl group; and R4 is a hydrogen atom. 
Spoj u skladu sa patentnim zahtjevom 35 ili njegova farmakološki prihvatljiva sol, gdje A je cikloheksil grupa supstituirana metil grupom ili etil grupom; i R4 je atom vodika.
A pharmaceutical composition comprising a compound according to claim 1 or a pharmaceutically acceptable salt thereof. The pharmaceutical composition of claim 2 which further includes an excipient. 
Farmaceutski sastav, naznačen time, da obuhvaća spoj prema zahtjevu 1 ili njegovu faramceutski prihvatljivu sol, te farmaceutski prihvatljiv nosač.
an adjuvated proteinaceous antigen; wherein said recombinant adenovirus is selected from the group consisting of human adenovirus serotype 11, 24, 26, 34, 35, 48, 49 and 50, and wherein said replication-defective recombinant adenovirus is a priming composition and said adjuvated proteinaceous antigen is a boosting composition. 
- - adjuvantirani proteinski antigen; gdje se navedeni rekombinantni adenovirus bira iz skupine koju čine ljudski adenovirus, serotip 11, 24, 26, 34, 35, 48, 49 1 50, te gdje je navedeni replikacijski deficijentni rekombinantni adenovirusni inicijalni pripravak, a navedeni adjuvantirani proteinski antigen je pojačivački pripravak.